Latham & Watkins Advises CytomX in Strategic Research Collaboration With Moderna

CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, have announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody® therapeutic platform.

Latham & Watkins LLP advised CytomX in the transaction with a licensing deal team led by Bay Area partner Judith Hasko, with Los Angeles associate Mike Sweeney. Bay Area partner Mark Roeder, with Bay Area associates Tess Bloom and Natalie Robertson, advised on corporate aspects of the transaction.